NCT05970627View on ClinicalTrials.gov

Perioperative Chemotherapy Plus Toripalimab for Epstein-Barr Virus-associated Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 28, 2023

Primary Completion Date

July 28, 2026

Study Completion Date

July 28, 2029

Conditions
Adenocarcinoma of the StomachAdenocarcinoma of Esophagogastric JunctionEpstein-Barr Virus-Associated Gastric Carcinoma
Interventions
DRUG

Toripalimab

Perioperative Toripalimab, 240 mg IV infusion

DRUG

Oxaliplatin

Oxaliplatin (130 mg/m2) infusion as perioperative chemotherapy

DRUG

S1

S-1 orally intake as perioperative chemotherapy

Trial Locations (8)

310003

The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou

The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou

313099

Huzhou Central Hospital, Huzhou

315010

Ningbo First Hospital, Ningbo

315048

Ningbo Medical Center LiHuiLi Hospital, Ningbo

315099

Ningbo Second Hospital, Ningbo

317099

Taizhou Hospital, Taizhou

323000

Lishui Central Hospital, Lishui

All Listed Sponsors
lead

Yu jiren

OTHER